Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection

PLoS Pathogens

Volumn 10, Issue 1, 2014, Pages

  Liu, Jia ^a   Zhang, Ejuan ^a   Ma, Zhiyong ^a   Wu, Weimin ^a   Kosinska, Anna ^a   Zhang, Xiaoyong ^a,b   Möller, Inga ^a   Seiz, Pia ^c   Glebe, Dieter ^c   Wang, Baoju ^d   Yang, Dongliang ^d   Lu, Mengji ^a   Roggendorf, Michael ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD274 PROTEIN, MOUSE; DNA VACCINE; ENTECAVIR; GUANINE; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; VIRUS VACCINE;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CD8+ T LYMPHOCYTE; DRUG EFFECTS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MARMOTA; MOUSE; PATHOLOGY; PHYSIOLOGY; VACCINATION; VIRUS REPLICATION; WOODCHUCK HEPATITIS VIRUS;

ANIMALS; ANTIGENS, CD274; ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; GUANINE; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; MARMOTA; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR; VACCINATION; VACCINES, DNA; VIRAL VACCINES; VIRUS REPLICATION;

EID: 84893805242     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003856     Document Type: Article

References (53)

1. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, et al. (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365: 123-129.
2. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, et al. (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352: 2682-2695.
3. Locarnini S, Mason WS, (2006) Cellular and virological mechanisms of HBV drug resistance. J Hepatol 44: 422-431.
4. Zoulim F, Locarnini S, (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137: 1593-1608 e1591-1592.
5. Klenerman P, Hill A, (2005) T cells and viral persistence: lessons from diverse infections. Nat Immunol 6: 873-879.
6. von Herrath MG, Berger DP, Homann D, Tishon T, Sette A, et al. (2000) Vaccination to treat persistent viral infection. Virology 268: 411-419.
7. Dikici B, Kalayci AG, Ozgenc F, Bosnak M, Davutoglu M, et al. (2003) Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr Infect Dis J 22: 345-349.
8. Nevens F, Roskams T, Van Vlierberghe H, Horsmans Y, Sprengers D, et al. (2003) A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38: 1289-1296.
9. Wherry EJ, Blattman JN, Ahmed R, (2005) Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol 79: 8960-8968.
10. Nisii C, Tempestilli M, Agrati C, Poccia F, Tocci G, et al. (2006) Accumulation of dysfunctional effector CD8+ T cells in the liver of patients with chronic HCV infection. J Hepatol 44: 475-483.
11. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
12. Maier H, Isogawa M, Freeman GJ, Chisari FV, (2007) PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 178: 2714-2720.
13. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, et al. (2009) Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458: 206-210.
14. Finnefrock AC, Tang A, Li F, Freed DC, Feng M, et al. (2009) PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol 182: 980-987.
15. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH, (2006) Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 203: 2223-2227.
16. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, et al. (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81: 4215-4225.
17. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
18. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, et al. (2006) Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12: 1198-1202.
19. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, et al. (2006) PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 203: 2281-2292.
20. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, et al. (2007) Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 45: 588-601.
21. Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, et al. (2007) HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 133: 1132-1143.
22. Ha SJ, Mueller SN, Wherry EJ, Barber DL, Aubert RD, et al. (2008) Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 205: 543-555.
23. Lu M, Yao X, Xu Y, Lorenz H, Dahmen U, et al. (2008) Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol 82: 2598-2603.
24. Zhang E, Zhang X, Liu J, Wang B, Tian Y, et al. (2011) The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection. PLoS One 6: e26196.
25. Burshtyn DN, Lam AS, Weston M, Gupta N, Warmerdam PA, et al. (1999) Conserved residues amino-terminal of cytoplasmic tyrosines contribute to the SHP-1-mediated inhibitory function of killer cell Ig-like receptors. J Immunol 162: 897-902.
26. Sidorenko SP, Clark EA, (2003) The dual-function CD150 receptor subfamily: the viral attraction. Nat Immunol 4: 19-24.
27. Zhang Z, Zhang JY, Wherry EJ, Jin B, Xu B, et al. (2008) Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 134: 1938-1949, 1949 e1931-1933.
28. Frank I, Budde C, Fiedler M, Dahmen U, Viazov S, et al. (2007) Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide. J Virol 81: 7156-7163.
29. Kosinska AD, Johrden L, Zhang E, Fiedler M, Mayer A, et al. (2012) DNA Prime-Adenovirus Boost Immunization Induces a Vigorous and Multifunctional T-Cell Response against Hepadnaviral Proteins in the Mouse and Woodchuck Model. J Virol 86: 9297-9310.
30. Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, et al. (2013) Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS pathogens 9: e1003391.
31. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, et al. (2007) Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27: 670-684.
32. Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, et al. (2004) Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 78: 5707-5719.
33. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, et al. (2000) The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191: 1269-1280.
34. Pol S, Driss F, Michel ML, Nalpas B, Berthelot P, et al. (1994) Specific vaccine therapy in chronic hepatitis B infection. Lancet 344: 342.
35. Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, et al. (2001) Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 34: 917-921.
36. Yalcin K, Acar M, Degertekin H, (2003) Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection 31: 221-225.
37. Hel Z, Venzon D, Poudyal M, Tsai WP, Giuliani L, et al. (2000) Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med 6: 1140-1146.
38. Tryniszewska E, Nacsa J, Lewis MG, Silvera P, Montefiori D, et al. (2002) Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol 169: 5347-5357.
39. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, et al. (2010) Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138: 682-693, 693 e681-684.
40. Blackburn SD, Shin H, Freeman GJ, Wherry EJ, (2008) Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A 105: 15016-15021.
41. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, et al. (2011) Clinical applications of DNA vaccines: current progress. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 53: 296-302.
42. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
43. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465.
44. Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, et al. (2011) Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53: 1494-1503.
45. Wu W, Shi Y, Li S, Zhang Y, Liu Y, et al. (2012) Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B. European journal of immunology 42: 1180-1191.
46. Li FJ, Zhang Y, Jin GX, Yao L, Wu DQ, (2013) Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunology letters 150: 116-122.
47. Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, et al. (2013) GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144: 1508-1517, 1517 e1501-1510.
48. Crettaz J, Otano I, Ochoa-Callejero L, Benito A, Paneda A, et al. (2009) Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12. J Virol 83: 2663-2674.
49. Lu M, Hilken G, Kruppenbacher J, Kemper T, Schirmbeck R, et al. (1999) Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J Virol 73: 281-289.
50. Lu M, Isogawa M, Xu Y, Hilken G, (2005) Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks. J Virol 79: 6368-6376.
51. Lu M, Lohrengel B, Hilken G, Kemper T, Roggendorf M, (2002) Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes. J Virol 76: 58-67.
52. Zhang X, Meng Z, Qiu S, Xu Y, Yang D, et al. (2009) Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways. Cell Microbiol 11: 1624-1637.
53. Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, et al. (2001) Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. The Journal of infectious diseases 184: 1236-1245.